Last reviewed · How we verify
NCT06232421: OLENKRON-01
A Prospective, Parallel, Single-blind Clinical Study Using Stratified Randomization of the Effectiveness, Tolerability and Safety of the Medicinal Product "Foscelantan, Medicinal Plate 4.0x5.0 cm in Package No. 1" Produced by UNITEKHPROM BSU, Republic of Belarus, in Comparison With the Medicinal Product Povidone- Iodine Produced by BelAseptika JSC, in Adult Patients With Purulent-inflammatory Processes of the Skin and Soft Tissues Due to the Neuropathic Form of Diabetic Foot Syndrome or Chronic Venous Insufficiency, Phase I-II of the Wound Process
Phase 2/Phase 3 trial testing Foscelantan in Diabetic Foot Infections in 224 participants. Not yet recruiting.
1 April 2026
Quick facts
| Lead sponsor | Research Institute for Physical Chemical Problems of the Belarusian State University |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 224 |
| Start date | 1 November 2025 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 2 locations across Belarus |
Drugs / interventions tested
- Foscelantan — full drug profile →
- Povidon-iodine — full drug profile →
Conditions studied
- Diabetic Foot Infections — all drugs for Diabetic Foot Infections →
- Chronic Venous Insufficiency — all drugs for Chronic Venous Insufficiency →
Sponsor
Research Institute for Physical Chemical Problems of the Belarusian State University
Who can join
Adults 18 to 70, any sex, with Diabetic Foot Infections or Chronic Venous Insufficiency. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Number of patients with trophic ulcers cured
Time frame: 15 days
Number of patients cured
Sponsor's own description
The purpose of this study is to estimate efficiency, tolerance, safety of "Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1" among adult patients who have purulent-inflammatory processes of the skin and soft tissues due to the neuropathic form of diabetic foot syndrome or chronic venous insufficiency, phase I-II of the wound process.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06232421
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06232421 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Research Institute for Physical Chemical Problems of the Belarusian State University
- Last refreshed: 22 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06232421.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing